aeruginosa colonization (over 5 years) revealed the highest tobramycin MICs (MIC50=1.00 and MIC90>1024 mu g/ml). In conclusion, tobramycin has excellent in vitro activity against the studied GSI-IX in vivo CF isolates. Some factors such as isolate morphotype, pre-administration of TSI and duration of colonization influence its activity. Whenever TSI is considered for therapy, the CF P. aeruginosa strains categorized as intermediate or

resistant to tobramycin according to the CLSI criteria should be recategorized by using the MENSURA interpretive criteria.”
“During technology development, the study of ultralow-k (ULK) time-dependent dielectric breakdown (TDDB) is important for assuring robust reliability. As the technology advances, the increase in ULK leakage current noise level and reversible current change induced by soft breakdown (SBD) during stress has been observed. In this paper, the physical origin of SBD and reversible breakdown, and its correlation to conventional hard breakdowns (HBDs) were extensively studied. Based on constant voltage stress (CVS) and constant current stress (CCS) results, it was concluded that SBD in ULK is an intrinsic characteristic for ULK material, and all first breakdown events most likely are soft instead of hard. Therefore, a unified understanding of SBD and HBD for low-k TDDB was established. Furthermore, the post-SBD and

HBD breakdown conduction characteristics were explored and their impacts on circuit operation were discussed. Based on current limited constant voltage stress studies, it was found that the power dissipation, not the stored energy, determined the severity of ULK dielectric breakdown, and the postbreakdown GW2580 in vitro conduction properties. A percolation-threshold controlled, variable-range-hopping (VRH) model was proposed to explain all postbreakdown aspects of SBD and HBD of ULK material. (C) 2010 American Institute of Physics. [doi:10.1063/1.3476292]“
“Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies. DORI-05, a randomized, double-blind study compared doripenem 500 mg every 8 hours with levofloxacin 250 mg every 24 hours. DORI-06 was a single-arm

study designed to confirm the doripenem response in DORI-05. 799 received doripenem, 372 levofloxacin. Microbiological eradication rates in microbiologically HM781-36B cost evaluable populations were 82.8% for doripenem, 83.4% for levofloxacin (Delta: -0.6%; 95% confidence interval: -6.4, 5.2), and 80.9% and 78.2%, respectively (Delta: 2.7%; 95% confidence interval: -3.0, 8.3) in the co-primary microbiologically modified intent-to-treat populations. Clinical cure rates in the clinically evaluable populations were 94.1% for doripenem, 90.2% for levofloxacin (Delta: 3.9%; 95% confidence interval: -0.5, 8.2). In subjects infected with levofloxacin-resistant Escherichia coil, outcomes were statistically significantly greater with doripenem. Genotyping data indicate persistent E.